One unexpected finding was the more robust and functionally competent vaccine-induced CD8 T cell response after SARS-CoV-2 mRNA vaccination in the patients with MS treated with aCD20, especially patients who failed to generate anti-RBD IgG. This evidence concerns the gene CD8A and myeloid sarcoma.